Key facts
- RADiCAIT’s last known valuation is $5.0M (Aug 2025).
- It has raised $2.0M; the latest was Seed Round ($1.7M) in Oct 2025.
- Notable investors include Techstars, University of Oxford, Frontline Ventures, Gurtin Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for RADiCAIT
- ·The full record, as it builds
Funding rounds
No funding rounds for RADiCAIT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RADiCAIT
Operator of a medical imaging technology company intended to improve the accessibility and affordability of PET scans. The company uses artificial intelligence to create synthetic PET images from CT scans and eliminate the need for radioactive tracers and reduce the reliance on specialized scanners and chemical-nuclear infrastructure, enabling users to make radiology more accessible, productive, safe and sustainable.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 5
- Website
- radicait.com/
- Ownership
- Privately Held (backing)
RADiCAIT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RADiCAIT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RADiCAIT in its N-PORT filings yet. We sweep new filings monthly.